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Purpose. To describe healthcare consumption and costs prior to, during, and after multidisciplinary rehabilitation due to arthritis.
Methods. 306 patients (age 18–75 years) with arthritis scheduled for multidisciplinary rehabilitation care in 9 rehabilitation centres
and 4 rheumatology hospital departments were included and followed for 6 months. Costs were estimated in Euros (C)f o rt h e
total sample and ﬁve clinical subgroups. Results. Healthcare costs ranged from C3,033 to C91,336 and were signiﬁcantly higher
at hospital departments compared to rehabilitation centres: C9,722 (SD 5,406) and C4,250 (SD 1,040). While total costs prior
to and after rehabilitation were stable for those receiving rehabilitation at a hospital, there was a signiﬁcant increase in costs for
those being at a rehabilitation centre. Total mean costs were more than doubled when including social costs: from C32,410 (95%
CI 20,074–37,017) to C51,491 (95% CI 49,055–61,657). Conclusions. Healthcare and social costs for arthritis rehabilitation were
substantial both before and after a rehabilitation stay. It is important to explore methods to reduce the length of rehabilitation stay
and production loss connected to rehabilitation of patients with rheumatic disease.
1.Introduction
Despite advances in pharmacological treatment, work dis-
abilityamongindividualswithchronicarthritisissubstantial
[1], and nonpharmacological treatment and rehabilitation
are necessary for many individuals. In Norway there has
been a large increase in disability pension due to rheumatoid
arthritis, osteoarthritis, and soft tissue rheumatism during
the past 30 years [2]. Since arthritis patients contain a
substantial share of patients in the healthcare sector, it is
important to estimate both the use and need for healthcare
servicesandrelatedcosts.Estimation ofcostswillallowmore
informed judgements on disease management.
In Norway, multidisciplinary rehabilitation care for
patients with inﬂammatory or noninﬂammatory arthritis
is available in rheumatology departments at national, and
regional hospitals and in specialised rehabilitation centres.
Rheumatology hospital departments oﬀer multidisciplinary
rehabilitation care through in- and outpatient programmes,
and the teams usually consist of several types of health
professionals, for example, rheumatologist, nurse, physical
therapist, occupational therapist, social worker, and psy-
chologist. The teams in the rehabilitation centres are often
limited to rheumatologist, nurse, and physical therapist, and
hence, there is a less costly health service. There exists no
unanimous practice for referring arthritis patients in need
of rehabilitation care to a hospital or a rehabilitation centre.
However, since patients referred to a rehabilitation centre
must be able to take care of basic self care activities, it is
expected that these patients have a lower level of disease
severity, for example, as measured by physical function
outcomes. Similarly, it is expected that patients, who can2 Rehabilitation Research and Practice
attend outpatient rehabilitation programmes at hospitals,
have less activity limitations than patients in need of
inpatient multidisciplinary rehabilitation care.
A few previous studies have shown that multidisciplinary
rehabilitation care, provided in outpatient rehabilitation
programmes, has signiﬁcantly lower costs than inpatient
programmes [3–5]. In an observation study from Germany
[6] the costs of inpatient rehabilitation for musculoskeletal
disorders (mostly rheumatoid arthritis and back pain)
also were signiﬁcantly higher as compared to outpatient
rehabilitation with mean cost estimates of Euro (C) 2047
versus C1111 in inpatient/outpatient, respectively. Other
observational studies of inﬂammatory arthritis patients in
hospitals report that total costs are signiﬁcantly inﬂuenced
by severity of the disease, such as level of pain, presence
of rheumatoid factor, and grip strength [7]. Despite that
there have been several costs of illness studies for patients
with various arthritis diseases [6–12], few studies so far have
studied the healthcare consumption and related costs among
people who are in need of rehabilitation due to arthritis.
The purpose of this study was to describe healthcare
consumption and related costs over a period 3 months prior
to, during, and 6 months after receiving multidisciplinary
rehabilitation care for various clinical subgroups of patients
with inﬂammatory or noninﬂammatory arthritis. A second
aim was to investigate the eﬀect of diagnosis, clinical setting,
age, gender, severity of disease, comorbidity, and work status
on total healthcare costs. We expected that patients with
arthritishadareducedneedforhealthcareintheﬁrstmonths
following multidisciplinary rehabilitation care of at least one
week duration. Further, we expected that the healthcare
costs were higher by higher age, higher severity of disease
(as measured by diagnosis, physical function outcomes, co-
morbid conditions), for patients who were on sick leave, and
higher among patients referred to a rehabilitation stay in a
hospital as compared to a rehabilitation centre.
2. Methods
2.1. Design and Setting. This was a multicenter, longitudinal
observational study in which all institutions/hospital units,
which provided multidisciplinary rehabilitation care, in
South-EastNorwaywereinvitedtoparticipate.Therewere15
rehabilitation centres and 4 rheumatology units in hospital
eligible, of which 9 specialised rehabilitation centres and the
4 rheumatology hospital departments agreed to participate
in the study. Eligible patients at the participating centres
wereconsecutivelyrecruitedoverathree-monthperiodfrom
September to December in 2006 and followed in 6 months
after discharge.
2.2. Patients. All patients aged 18 to 75 years with an
inﬂammatory joint disease or osteoarthritis of any location
and scheduled for a rehabilitation stay of at least one week
were invited to participate in the study. Patients diagnosis
was conﬁrmed by a rheumatologist at each of the clinical
sites. Exclusion criteria were serious psychiatric comor-
bidity or inability to communicate in written Norwegian.
The patients were recruited by research assistants at the insti-
tutions/departments, who provided information about the
study to the patients, including informed agreement and
written consent. The study was approved by the regional
committee for medical research ethics.
2.3. Demographic and Health Status Data. At admission
physicians examined the patients and provided diagnos-
tic information. The patients ﬁlled in a comprehensive
questionnaire at admission and discharge and a postal
questionnaire at six-month follow-up. The baseline ques-
tionnaire included sociodemographic and health status vari-
ables. Sociodemographic variables concerned age, gender,
level of education, work status, co-morbidity (number of
diseases from a list of 12 possible diagnostic groups),
use of medication (pain, inﬂammatory, relaxation), and
use of assistive tools. Health outcomes were the Modiﬁed
HealthAssessmentQuestionnaire (MHAQ)[13] and thetwo
component summary scores of the Short-Form 36-item (SF-
36) Health Survey [14]. The SF36 Physical and Mental sum
scores were derived from the eight subscales, scored from 0
to 100 where 100 is the best possible functioning. In MHAQ
e a c hq u e s t i o ni sg r a d e df r o m0t o3w h e r e0i s“ w i t h o u ta n y
eﬀort” and 3 is “not capable”, which give an overall mean
score.
2.4. Healthcare Consumption and Costs. Use of health care
services during the 3-month period before the rehabilitation
stay was collected in the baseline questionnaire before the
patients started their rehabilitation. Use of health care
servicesinthe6-monthfollow-upwasrecordedbyamonthly
cost diary, including registrations of number of visits to a
general practitioner, physical or manual therapist, medical
specialist, social worker, and alternative therapist, number
of days of hospitalization and/or rehabilitation, use of
medication (both on prescription and over the counter
medication), and number of days of sick leave from work.
Diﬀerent types of healthcare costs are presented in four cost
groups: cost group 1 considers costs for primary healthcare
services, cost group 2 for secondary healthcare services, cost
group 3 covers use of medication, and cost group 4 provides
costsforproductionlossforemployedpatients.Thefourcost
groups are presented in Table 1.
Information on cost per unit was collected from diﬀerent
sources (Table 1). Costs per unit for visits to the gen-
eral practitioner, specialists, and out-patient rehabilitation,
which were collected from Norwegian Labour and Welfare
Administration (NAV), were based on the fee for service
compensation, where the copayment and fee for service on
average represent 40% of the cost per consultation (Ministry
of Health and Care Services, 2003).
The rehabilitation length was calculated as number
of days between admission and discharge, including the
weekends (7 days per week). Costs incurred at the hospital
werebasedondiagnosis-relatedgroups(DRGs)2006.DRGis
an international coding system, used for administrating both
clinical and ﬁnancial activity, in the specialist health care. In
Norway there are about 500 DRG groups. All DRG groupsRehabilitation Research and Practice 3
Table 1: Cost categories, units, valuation, and unit price, all numbers in EURO (C).
Cost categories Unit Valuation Unit price C1
Primary care (cost group 1)
General practitioner Visits NAV 38
Specialist (several types) Visits NAV 171
Physiotherapy2 Per treatment Charge 38
Manual therapy2 Per treatment Charge 41
Chiropractor2 Per treatment Charge 63
Occupational therapy2 Per treatment Charge 41
Others (psychologist, social worker, nurse,
practical assistant other types)2 Per treatment Charge 38
Alternative treatment3 Visits Out of pocket From 29 to 1,625
Hospitalizations/inpatient stays (cost group 2)
Rehabilitation centre Days Direct communication 188
Hospital inpatient unit Days DRG 462 B 711
Hospital outpatient unit Days NAV 195
Hip/knee prosthesis surgery Per patient DRG 211 17,783
Inpatient hospital stay before/after rehab stay Days DRG-average 1,193
Medication (cost group 3)
Abatacept (Orencia) 3 set ` a 250mg Price per month 511
Etnaercept (Enbrel) 4 sett (50mg) Price per month 665
Adalmimumab, ikke adalmimumab (Humira) 40mg ∗ 2 Price per month 1,312
Inﬂiximab (Remicade) 3mg per kilo (300mg) ∗ 0.5 Price per month 2,201
Tocilizumab (Ro-Actemra) 8mg per kilo (400mg) ∗ 2 Price per month 1,246
Anakinra (Kineret) 100mg per day ∗ 30 Price per month 1,016
Leﬂunomide (Arava) 20mg 30 tablets Price per month 83
Other medication Price per month 25
Production loss (sick leave) (cost group 4)
Hours Wage rate per day 244
11C= 8N O K .
2Treatment time varies from 30 to 45 minutes.
3Treatment modalities such as acupuncture, homeopathy, Thai massage, and Turkey bath/spa rehab stay.
NAV: Norwegian Labor and Welfare Administration.
DRG: diagnosis-related groups.
are given a speciﬁc weight to reﬂect the treatment intensity
relative to the average patient. The cost for a DRG group
is estimated by multiplying the cost weight for that speciﬁc
DRGgroupwiththecostofoneDRG.In2006thecostofone
DRG was C3,513∗ (Norwegian Health Directorate, 2007).
When the DRG group was impossible to deﬁne, the unit cost
was based on an average DRG per day.
Unit cost for the diﬀerent types of treatment (physio-
therapy, manual therapy, etc.) was based on charges. For
the group “others” we used the lowest charge of the other
treatments as an estimate. Medication costs were based
on the price list from the Norwegian Medicines Agency.
The costs of acupuncture, homeopathy, and other types
of treatments were based on out of pocket cost reported
by the patients. The cost of sick leaves (for those who
were employed) is estimated to be equal to average income
inclusive social costs [15]. We thus apply the human capital
approach, assuming that the time one person is absent from
work is lost and is therefore a cost for society [16]. The costs
for medication use and sick leaves during the 6-month
follow-up were estimated as an average sum per month (for
all patients in the subgroups) according to the reporting in
the monthly diary. All costs were transformed to Euro (C)
with 1 C = 8N O K .
In Norway, the social security system covers almost
all costs related to hospital stay, including the costs for
medication and other treatments during the stay, and the
costs related to production loss. Furthermore, the social
security system covers the main costs for rehabilitation
stay and use of primary care health services for people
with a rheumatic disease diagnoses, whereas there is a
minor out-of-pocket payment for these services. The out-of-
pocket payment for a stay at the rehabilitation institutions
is in average C15. However, there is an upper limit for
out-of-pocket costs of approximately C250 for Norwegian
people. Exceptions are alternative treatments and treatment
procedures not referred by a medical doctor, which have to
be covered in total by the patient him/herself.4 Rehabilitation Research and Practice
2.5. Statistical Analysis. Continuous variables are presented
by means with standard deviations and categorical variables
are presented by frequencies and percentages for the total
sample and for each of the diagnostic subgroups. As the
cost data were highly skewed, we present the total costs
with both median (with min-max) and mean with standard
deviation. Cost estimates within the subgroups are presented
with mean and conﬁdence intervals, which were estimated
with the bootstrap method. For diﬀerences in trends within
thecostgroupsandbetweenclinicalsubgroups,weusedrank
sum based on “Kruskal-Wallis equality-of-populations rank
test” according to the clinical subgroups and time periods,
respectively.
When assessing associations between the total costs and
potential predictors, we used the total healthcare costs in
groups 1, 2, and 3 for the rehabilitation stay and the 6-
months follow-up as main outcome. The eﬀects of clinical
subgroup, age, gender, comorbidity, working status, baseline
scores of the MHAQ, SF36 physical and mental function,
and use of assistive tool were tested separately in the
inﬂammatory and non-inﬂammatory subgroups by means
of Ordinary Least Square regressions. Statistical analysis
was performed with SPSS 14.0 and STATA 10.5% level of
signiﬁcance was used.
3. Results
3.1. Sample Characteristics. Of 581 eligible patients a total
of 460 (72.2%) accepted to participate in the study. There
was incomplete diagnostic data for 3 patients, 23 patients
withdrew before they started the rehabilitation, and 70
patients dropped out in the period between discharge from
the rehabilitation stay and 6 months of follow-up. Of the 367
responders to 6-month follow-up 61 patients had lacking or
incomplete data for the use of healthcare, leaving a total of
306 patients for current analyses. There were no signiﬁcant
diﬀerences between the initial included study sample and
the ﬁnal set of 306 responders with regard to diagnostic
group, clinical setting, gender, work status, co-morbidity,
and baseline physical function (MHAQ and SF36 Physical
function sum score). The non responders, however, were
slightly younger, were more frequently single, and had lower
level of education and poorer mental health scores according
to the SF36 Mental health.
The mean age was 61 years (SD 9.6), 75% were female,
andthemajorityhadanoldage-ordisability-relatedpension
(68%) (Table 2). The majority of the patients had a primary
diagnosis of osteoarthritis (123 hip osteoarthritis, 58 knee
osteoarthritis, 14 polyarthritis) and approximately 36% of
the patients had an inﬂammatory arthritis diagnosis (42
rheumatoid arthritis, 47 ankylosing spondylitis, 15 connec-
tivetissuedisease,7polymyalgia).Nearlyallthepatientswith
osteoarthritis had rehabilitation at one of the rehabilitation
centres, whereas patients with inﬂammatory arthritis had
rehabilitation in either a hospital department (n = 60)
or rehabilitation centre (n = 60). A minor subgroup of
14 patients had rehabilitation due to inﬂammatory arthritis
in an outpatient clinic at one of the hospitals. Patients
at rehabilitation centres and hospital departments diﬀered
signiﬁcantly with regard to several of the sociodemographic
variables at baseline: for example, patients at the rehabilita-
tion centres were older, more likely to be female, and less
likely to be employed and had more co-morbid conditions.
Patients in the hospitals, however, used more inﬂammatory
medications and also tended to use more assistive tools.
There was, however, no statistical signiﬁcant diﬀerence
between the ﬁve subgroups with regard to use of assistive
tools and use of relaxing/sleeping medication.
The mean duration of the rehabilitation stay was sig-
niﬁcantly shorter at the hospital units (mean days 15.7,
SD 5.6) than at the rehabilitation institutions (mean days
22.7, SD 5.5) (P<. 001) (Table 2). At baseline the patients
with postsurgery osteoarthritis at the rehabilitation centres
had signiﬁcantly worse physical function according to both
MHAQandSF36Physicalfunctionscoresascomparedtothe
other subgroups (Table 2). The patients with an inﬂamma-
torydiagnosisreceivingrehabilitationintheoutpatientclinic
had best physical function scores and poorest SF 36 Mental
score.
3.2. Healthcare Consumption and Related Costs prior to,
during and after the Rehabilitation Stay. Mean costs related
to health consumption in the primary healthcare services
(cost group 1), secondary healthcare services (cost group 2),
use of medication (cost group 3), and production loss (cost
group 4) for each of the ﬁve subgroups prior to, during,
and after the rehabilitation stay are presented in Table 3.
The total costs for the rehabilitation stay were highest at
inpatient hospital departments with mean 15,723 (95%
CI; 13,705–17,874), whereas the costs were lowest for the
patients receiving rehabilitation at the outpatient hospital
department with mean 5,120 (3,835–5,272). The mean total
costsattherehabilitationcentreswere10,448(9,883–11,013)
for the inﬂammatory subgroup, 9,976 (8,870–10,121) for
the OA conventional subgroup, and 7,770 (6,586–7,824) for
the OA postsurgery subgroup. The direct costs contributed
mainly to the diﬀerences in total costs between the clinical
subgroups. Costs due to production loss were approximately
as high as the direct cost for the rehabilitation stay and
showedasimilarpatternacrosstheclinicalsubgroups.Forall
the clinical subgroups the costs related to inpatient hospital
care (cost group 2) and production loss (cost group 4)
accounted for the largest proportion of the total healthcare
costs, whereas the costs related to primary healthcare and
medication accounted for a minor part.
Healthcare consumption and costs during the 3-month
period prior to and 6-month period after multidisciplinary
rehabilitation care were similar with no signiﬁcant changes
within the two groups with inﬂammatory arthritis treated at
a hospital. For the three clinical subgroups receiving reha-
bilitation at a rehabilitation centre, there was a signiﬁcant
increase in mean costs due to healthcare consumption in
the primary care, whereas there was a signiﬁcant decrease
in mean costs of secondary healthcare services for the
two osteoarthritis subgroups. There was also a signiﬁcant
decrease in use of medication in the postsurgery osteoarthri-
tis subgroup across the time periods. Furthermore, the mean
costs due to medication use were higher among patientsRehabilitation Research and Practice 5
Table 2: Sociodemographic and health variables at baseline for the total sample (n = 306) and for each of the diagnostic subgroups at
hospital departments (n = 62) and rehabilitation centres (n = 244).
ALL N = 306
Inﬂamm. disease
hospital
(n = 48)
Inﬂamm. disease
outpatient
hospital
(n = 14)
Inﬂamm. disease
rehab centre
(n = 50)
OA conventional
rehab centre
(n = 63)
OA postsurgery
rehab
(n = 131)
Age (y), mean (SD) 60.7 (9.6) 54.4 (11.2) 51.6 (11.2) 58.2 (9.5) 60.7 (8.1) 64.9 (7.1)
Female, n (%) 229 (74.8) 26 (54.2) 10 (71.4) 48 (96.0) 61 (96.8) 84 (64.1)
Married/cohabitant, n
(%) 213 (69.6) 35 (74.5) 11 (78.5) 32 (66.7) 38 (60.3) 97 (75.8)
Education, n (%)
≤9 years 77 (25.2) 15 (31.9) 5 (35.7) 13 (26.5) 15 (24.2) 29 (22.8)
≤12 years 70 (22.9) 11 (23.4) 3 (21.4) 11 (22.4) 18 (29.0) 27 (21.3)
>12 years 152 (49.7) 21 (44.7) 6 (42.9) 25 (51.0) 29 (46.8) 71 (55.9)
Missing 7 1 — 1 1 4
Work situation, n (%)
Employed 40 (13.2) 10 (21.3) 7 (50.0) 6 (12.2) 8 (12.7) 9 (7.0)
Employed, but on
sick leave 50 (16.3) 4 (8.5) 4 (28.6) 4 (8.2) 10 (15.9) 28 (21.7)
Disability pension 111 (36.3) 23 (48.9) 2 (14.3) 29 (59.2) 29 (46.0) 25 (19.4)
Age pension 99 (32.4) 7 (14.9) 1 (7.1) 9 (18.4) 16 (25.4) 65 (50.4)
Homeworker 4 (1.3) 2 (4.2) 0 0 0 2 (1.6)
Unemployed 2 (0.7) 1 (2.1) 0 1 (2.0) 0 0
M i s s i n g 4 1—1—2
Co-morbidity, n (%)
None 52 (17.0) 14 (29.2) 5 (35.7) 4 (8.0) 5 (7.9) 24 (18.3)
One 106 (34.6) 17 (35.4) 4 (28.6) 19 (38.0) 11 (17.5) 55 (42.0)
Two or more 148 (48.4) 17 (35.4) 5 (35.7) 27 (54.0) 47 (74.6) 52 (39.7)
Daily use pain
medication, n (%) 152 (49.7) 23 (53.5) 15 (35.7) 23 (53.5) 3 (30.0) 20 (31.7)
Daily use
anti-inﬂammatory
medication, n (%)
93 (30.4) 24 (58.5) 6 (54.5) 17 (44.7) 36 (45.0) 93 (43.3)
Daily use
relaxing/sleeping med,
n (%)
51 (16.7) 5 (13.5) 2 (22.2) 12 (30.8) 12 (21.8) 20 (23.0)
Assistive tools, mean
(SD) 0.9 (1.8) 1.2 (2.0) 1.9 (2.8) 0.8 (1.7) 0.5 (1.4) 1.0 (1.7)
Days of rehab stay
mean (SD) 21.3 (6.2) 16.7 (5.8) 11.9 (2.0) 26.7 (5.9) 25.5 (4.8) 19.8 (3.8)
MHAQ1, mean (SD) .77 (.48) .71 (.46) .49 (.43) .63 (.46) .65 (.45) .94 (.46)
SF36 physical sum
score2, mean (SD) 30.5 (8.9) 34.1 (10.8) 38.3 (8.5) 31.4 (8.1) 30.5 (9.0) 27.8 (7.5)
SF36 mental sum
scores2, mean (SD) 49.1 (12.7) 47.7 (13.1) 42.6 (13.2) 46.1 (12.3) 48.3 (12.8) 52.0 (12.2)
OA: osteoarthritis; rehab: rehabilitation.
1MHAQ score 0–3, 0 = best possible score, 3 = worst possible score.
2SF-36 sum scores, score 0–100, 0 = worst possible score, 100 = best possible score.
3P-values refer to ANOVA analysis for continuous variables and Chi-square for categorical variable.
withaninﬂammatorydiagnosisascomparedtopatientswith
osteoarthritis within all the time periods.
The costs related to production loss were the highest
across all the clinical subgroups and were 2-3 times higher
than total healthcare costs (Table 4); the total mean costs of
primary care, secondary care, and medication (sum of cost
groups 1, 2, and 3) were more than doubled when including
the costs related to sick leave (sum of cost groups 1, 2, 3, and
4) from mean C32,410 (95% CI 20,074–37,017) to C51,491
(95% CI 49,055–61,657), respectively (Table 4).6 Rehabilitation Research and Practice
Table 3: Mean costs in Euro (C) with 95% Conﬁdence IntervalsB 3 months prior to, during, and 6 months after multidisciplinary
rehabilitation in various clinical subgroups; the costs are presented according to the four cost groups.
Cost group Pre rehab stay Rehabilitation stay 0–3 months post
rehab stay
4–6 months post
rehab stay P-value2
Inﬂamm. disease
hospital (n = 48) 1 378 (88–422) — 545 (87–595) 586 (110–649) .16
2 2,010 (−1,258–2,776) 11,884 (10,940–13,443) 3,808 (961–7,334) 1,073 (−1,475–1521) .61
3 640 (−172–850) 544 (261–587) 1,136 (190–1492) 1,136 (190–1492) .45∗
41 8,191 (3,209–9,039) 3,158 (2,559–3,296) 8,480 (3,721–9,335) 8,480 (3,721–9,335) .59∗
Inﬂamm. disease
outpatient
hospital (n = 14)
1 518 (248–645) — 652 (164–731) 600 (69–715) .54
2 1,448 (−1,991–2,385) 2,309 (1,628–2,374) 851 (−1,347–2,172) 85 (−2,035–104) .40
3 636 (−786–1,458) 371 (62–440) 637 (−813–1498) 637 (−813–1498) 1.000∗
41 6,059 (−532–8,516) 2,437 (1,891–2,522) 7,583 (1,410–9,849) 7,583 (1,410–9,849) .20∗
Inﬂamm. disease
rehab centre
(n = 50)
1 483 (362–606) — 830 (626–1,035) 802 (595–1,009) .01
2 1,411 (160–2,663) 5,010 (4,703–5,316) 522 (83–961) 814 (−236–1,865) .74
3 232 (−69–534) 665 (545–786) 231 (−64–526) 231 (−64–526) .76∗
41 9,637 (7,571–11,704) 4,773 (4,451–5,004) 10,215
(8,263–12,167)
10,215
(8,263–12,167) .77∗
OA conventional
rehab centre
(n = 63)
1 479 (181–533) — 897 (302–1,074) 990 (201–1,367) .005
2 2,629 (−691–3,447) 4,780 (4,098–4,855) 165 (−767–238) 1,070 (−1,410–714) .01
37 3 ( −530–72) 587 (336–600) 72 (−518–71) 72 (−518–71) .65∗
41 7,997 (3,058–8,703) 4,608 (4,074–4,679) 9,191 (4,589–9,888) 9,191 (4,589–9,888) .24∗
OA postsurgery
rehab (n = 131) 1 415 (138–448) — 1,009 (498–1,112) 659 (225–678) <.001
2 17,268 (17,142–19,899) 3,704 (3,065–3,733) 1,207 (−67–1,603) 579 (−1,656–714) <.001
39 9 ( −542–108) 430 (187–433) 89 (−505–91) 89 (−505–91) .002∗
41 4,863 (438–5,176) 3,636 (3,161–3,648) 6,153 (1,854–6,549) 6,153 (1,854–6,549) .21∗
Cost groups 1–4 refer to costs related to health consumption in the primary healthcare services (cost group 1), secondary healthcare services (cost group 2),
use of medication (cost group 3), and costs related to production loss in terms of sick leave (cost group 4). All costs are presented in Euros: 1C = 8N O K .
OA: osteoarthritis; rehab: rehabilitation
B = Bootstrap 95% conﬁdence interval.
1Production loss includes only sick leave for employed patients. Age and disability pension are not included.
2P-values refer to testing for diﬀerences between the three time periods 3 months prior to, 0 to 3 months, and 4 to 6 months after rehabilitation stay within
each of the clinical subgroups and cost group. Rank sum based on “Kruskal-Wallis equality-of-populations rank test” was used.
The arthritis-related healthcare costs (sum of cost groups
1, 2, and 3) ranged from C3,033 to C91,336 during the
approximately 10 months of observation. The surgically
treated osteoarthritis patients (receiving hip/knee prosthesis
before rehabilitation) and the inﬂammatory patients at
inpatient hospital departments incurred more than twice
healthcare costs than the other three clinical subgroups
(Table 4). When summing up all four Cost groups, including
the costs due to production loss, the costs ranged from
C5,714 to C134,859 during the observation period.
3.3. Factors Inﬂuencing Total Costs after Rehabilitation Stay.
The average total healthcare cost (sum of Cost groups 1, 2,
and 3) from inclusion in the multidisciplinary team rehab
stay until 6-month follow-up was mean C39,624 (95% CI
32,896–46,336). As MHAQ, SF36 Physical function, SF36
Mental health, and assistive tools all are variables indicating
health status, we estimated ﬁve diﬀerent models including
diﬀerent variables (Tables 5(a) and 5(b)).
For patients with inﬂammatory disease all the models
showed that the total costs in a hospital unit were signiﬁcant
more costly than rehabilitation in a hospital outpatient
and at a rehabilitation centre (Table 5(a)). Being in an
inpatient hospital unit implies an increase in total costs
with about C13,000 during rehabilitation and 6 months
after the rehabilitation stay. Female gender, use of assistive
tools, and poor physical function in terms of either MHAQ
or SF36 Physical function also had a signiﬁcant eﬀect on
thehealthcarecosts.ThecorrelationbetweentheMHAQand
use of assistive tools could explain why MHAQ did not haveRehabilitation Research and Practice 7
Table 4: Mean (SD) and median (min-max) health care costs (summary of 1, 2, and 3) and health care- and social costs (summary of 1, 2,
3, and 4) for the whole observation period. Costs are in Euro (C).
Inﬂamm. disease
hospital (n = 48)
Inﬂamm. disease
outpatient hospital
(n = 14)
Inﬂamm. disease
rehab centre (n = 50)
OA conventional
rehab centre (n = 63)
OA postsurgery rehab
(n = 131)
C o s tg r o u p1 ,2a n d3
including rehab stay
Mean (SD) 23,605 (17,399) 8,749 (7,971) 11,038 (7,998) 11,817 (8,978) 25,136 (7,298)
Median
(min-max) 15,145 (7,779–91,336) 5,208 (3,033–27,687) 8,575 (3,900–38,793) 8,019 (5,006–46,703) 24,239 (4,539–48,468)
C o s tg r o u p1 ,2 ,3
and 4 including
rehab stay
Mean (SD) 51,492 (29,894) 32,410 (24,498) 45,880 (24,109) 42,804 (24,288) 45,952 (20,889)
Median
(min-max) 59,986 (32,410–24,498) 24,993 (5,714–73,993) 57,801 (8,040–92,906) 52,065 (9,196–89,801) 40,993 (7,951–90,491)
Cost groups 1–4 refer to costs related to health consumption in the primary healthcare services (cost group 1), secondary healthcare services (cost group 2),
use of medication (cost group 3), and costs related to production loss in terms of sick leave (cost group 4). All costs are presented in Euros: 1C = 8N O K .
OA: osteoarthritis; rehab: rehabilitation.
P-values refer to Kruskal Wallis testing for diﬀerences within period and cost group, but between diagnostic and clinical setting.
a signiﬁcant eﬀect in Models 1 and 3. In these models, age,
work status, comorbidity, and mental function did not have
an eﬀect on use of health care services among patients with
inﬂammatory arthritis.
For the patients with osteoarthritis there was no signif-
icant diﬀerence in total costs across the other three clinical
subgroups at the rehabilitation centres (Table 5(b)). Only
female gender had a signiﬁcant eﬀect on the costs, whereas
age, work status, comorbidity, physical and mental status,
and use of assistive tools had no inﬂuence on the total
healthcare costs during rehabilitation and 6 months after the
rehabilitation stay.
4. Discussion
This study provides a descriptive analysis of direct and
indirect costs incurred by various subgroups of patients
with inﬂammatory or non-inﬂammatory arthritis receiving
multidisciplinary rehabilitation care. Three main ﬁndings
were observed: ﬁrst, the total healthcare costs ranged from
C3,033 to C91,336 and were signiﬁcantly higher at hospital
departments compared to rehabilitation centres with mean
C9,722 (SD 5,406) and C4,250 (SD 1,040), respectively.
Second, while total costs prior to and after rehabilitation
were stable for those receiving rehabilitation at a hospital,
there was a signiﬁcant increase in costs for the three clinical
subgroups at a rehabilitation centre. Third, increased total
healthcare costs were associated with having rehabilitation
in an inpatient hospital department, being a women, using
assistive tools, and having reduced physical function in
patients with inﬂammatory arthritis, whereas only female
gender inﬂuenced healthcare costs among patients with non-
inﬂammatory arthritis. These ﬁndings indicate that—for
chronic conditions like rheumatic diseases—it is important
to look at healthcare consumption and related costs in a
wider time perspective than only the rehabilitation period.
In general, vast cost discrepancies have been reported
across studies [17] and across diagnostic subgroups within
rheumatic diseases [18]. For example, Flipon et al. [7]f o u n d
that costs in 2003 attributable to inﬂammatory arthritis
such as rheumatoid arthritis were C6,000 and C2,400 for
undiﬀerentiated arthritis. In a more recent review of cost-
of-illness studies from 2007 the yearly cost estimates of
rheumatoid arthritis ranged from 11,717 to 28,498 Canadian
Dollars (CAD) depending on the method [19].
Overall, in-patient hospital costs accounted for the
largest proportion of direct healthcare costs, whereas
the costs related to primary healthcare and medication
accountedforlowercosts.Eventhoughtherehabilitationstay
at hospitals was signiﬁcantly shorter than in rehabilitation
institutions (16 versus 23 days), the costs for rehabilitation
weresigniﬁcantlyhigheratthehospitals.Themainreasonfor
thisdiﬀerenceisthelargediﬀerenceinthepriceperday/night
per person in hospitals as compared to rehabilitation centres.
This ﬁnding is in line with our a priori expectations and also
with several previous studies [6, 7, 18] that have reported
that in-patient costs represent the largest proportions of
healthcare costs. The increase in costs for various subgroups
of patients can be defended if there are important reasons
to treat patients diﬀerently, for example, that a longer and
more resource-demanding rehabilitation intervention pro-
vides better outcome, and hence are more cost-eﬀective, or
that some patients need longer rehabilitation period because
they are more seriously aﬀected by the disease. In a previous
study [20] we found no signiﬁcant or clinically important
diﬀerences in physical or mental function between patients
with inﬂammatory disease receiving rehabilitation in the
rheumatology hospital departments and the rehabilitation
centres, despite that there were signiﬁcant diﬀerences in the
content of team rehabilitation across the clinical settings.
Twoprevioustrials,inwhichmultidisciplinaryrehabilitation
care was compared across diﬀerent clinical settings, reported8 Rehabilitation Research and Practice
Table 5
(a) The inﬂuence of clinical subgroup, age, gender, comorbidity, and work status on total health care costs (sum of cost groups 1 to 3 for rehabilitationp e r i o d
and 6 months after) for patients with inﬂammatory disease. The results are presented as Unstandardised Coeﬃcients (β) with 95% Conﬁdence intervals
Variable Model 1 Model 2 Model 3 Model 4
Clinical subgroup
Inﬂammatory disease rehab
center Ref. Ref. Ref. Ref.
Inﬂammatory disease
inpatient hospital unit
13,412
(8,744 to 18,080)∗∗
12,952
(8,299 to 17,605)∗∗
12,935
(8,173 to 17697)∗∗
13,721
(8,806 to 18,635)∗∗
Inﬂammatory disease
outpatient hospital unit
−2,595
(−9,388 to 4,196)
−2,406
(−5,875 to 3,727)
−2,560
(−9,514 to 4,395)
−73
(−7,089 to 6,940)
Gender (ref. female) Male
−2,968
(−8,055 to 2,118)
−3,272
(−8,371 to 1,826)
−3,555
(−8,744 to 1,633)∗
−4,025
(−9,402 to 1,352)
Age (ref. 67 or less) 68+ 1,682
(−4,712 to 8,077)
1,843
(−4,583 to 8,271)
4,430
(−1,762 to 10,624)
4,045
(−2,379 to 10,469)
Comorbidity (ref. none)
One 3,170
(−2,373 to 8,714)
3,291
(−2,282 to 8,864)
3,795
(−1,849 to 9,439)
4,851
(−1,002 to 10,632)
Two or more 2,939
(−2,830 to 8,708)
2,274
(−3,457 to 8,005)
2,885
(−3,003 to 8,775)
3,346
(−2,759 to 9,452)
Working status (ref. employed)
Not employed
1,732
(−3,288 to 6,753)
1,716
(−3,333 to 6,765)
448
(−4,589 to 5,485)
402
(−4,827 to 5,632)
MHAQ
−5,179
(−12,174 to 1,815) — 1,151
(−4,092 to 6,396)
4,122
(−921 to 9,166)∗
SF Physical function
−172
(−301 to −42)∗∗
−106
(−202 to −11)∗ ——
SF Mental function
−1
(−21to 19)
41
(−21 to 19) ——
Assistive tools 1,447
(414 to 2,540)∗∗
1,315
(268 to 2,361)∗
1,619
(542 to 2,695)∗∗ —
Constant 16,367
(4,568 to 28,168)∗∗
10,292
(10763 to 18,819)∗∗
3,367
(−3,134 to 9,869)
2,178
(−4,522 to 8,878)
Adj R-squared 0.3593 0.3518 0.3276 0.2750
C o s tv a l u e s( i nE u r o )a r ee s t i m a t e dm e a n sb yO L S .A l lc o s t sa r ep r e s e n t e di nE u r o s :1C= 8N O K .
∗P-value < .05, ∗∗P-value < .01.
The diﬀerence between the three models is only the inclusion of diﬀerent severity measures in addition to clinical setting, diagnosis, age, gender, and working
status.
Model 1: all severity measures are included: MHAQ, SF36 Physical function, SF36 Mental function, and assistive tools.
Model 2: we include only SF36 Physical function, SF36 Mental function and assistive tools.
Model 3: we include only MHAQ and assistive tools.
Model 4: we include only MHAQ.
(b) The inﬂuence of clinical subgroup, age, gender, comorbidity, and work status on total health care costs (sum of cost groups 1 to 3 for rehabilitationp e ri o d
and 6 months after) for patients with osteoarthritis (OA). The results are presented as Unstandardised Coeﬃcients (β) with 95% Conﬁdence intervals
Variable Model 1 Model 2 Model 3 Model 4
Clinical subgroup
OA (ref. conventional
rehabilitation) Ref. Ref. Ref. Ref.
OA postsurgery rehabilitation
−675
(−2,664 to 1,313)
−220
(−2,135 to 1,694)
−683
(−2,658 to 1,290)
−57
(−2,723 to1,207)
Gender (ref. female) Male
−2,086
(−4,166 to −6)∗
−2,037
(−4,125 to −50)
−2,103
(−4,142 to −65)∗
1,915
(−3,903 to 72)
Age (ref. 67 or less) 68+ 651
(−1,282 to 2585)
386
(−1,527 to 2,300)
693
(−1,217 to 2,605)
578
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(b) Continued.
Comorbidity (ref. none)
One 1,054
(−1,445 to 3,554)
1,080
(−1,429 to 3,590)
1,178
(−1,265 to 3,622)
1,148
(−1,292 to 3,589)
Two or more 1,341
(−1,160 to 3,842)
1,470
(−1,036 to 3,977)
1,514
(−891 to 3,920)
1,507
(−335 to 3,163)
Working status (ref. employed)
Not employed 192 (−1,805 to 2,190) −34 (−2,020 to 1,951) 263
(−1,707 to 2,234)
128
(−1,814 to 2,072)
MHAQ 1,512
(−365 to 3,390) — 1,614
(−199 to 3,428)
1,414
(−335 to 3,163)
SF Physical function
−2
(−13 to 9)
−4
(−15 to 6) ——
SF Mental function
−1
(−9t o6 )
−2
(−9t o6 ) ——
Assistive tools −216 (−738 to 305) −106 (−612 to 399) −220 (−739 to 299) —
Variable Model 1 Model 2 Model 3 Model 4
Constant 6,592
(3,301 to 9,882)∗∗
7,650
(4,621 to 10,679)∗∗
6,158
(3,303 to 9,013)∗∗
6,244
(3,399 to 9,090)∗∗
Adj R-squared 0.0101 0.0128 0.0193 0.0209
Cost values (in Euro) are estimated means by OLS. All costs are presented in Euros: 1C = 8N O K .
∗P-value < .05, ∗∗ P-value < .01.
The diﬀerence between the three models is only the inclusion of diﬀerent severity measures in addition to clinical setting, diagnosis, age, gender and working
status.
Model 1: all severity measures are included: MHAQ, SF36 Physical function, SF36 Mental function, and assistive tools.
Model 2: we include only SF36 Physical function, SF36 Mental function, and assistive tools.
Model 3: we include only MHAQ and assistive tools.
Model 4: we include only MHAQ.
a similar ﬁnding [3, 4]. Both studies found no signiﬁcant
diﬀerences in clinical outcomes, but signiﬁcantly lower costs
in the outpatient clinic as compared to the in-patient pro-
gram. Moreover, contrary to our expectations, the severity
of the inﬂammatory disease groups was similar across the
clinical rehabilitation settings at baseline, thus suggesting
that severity cannot explain why some patients were referred
to an inpatient hospital stay or a rehabilitation stay. On
the other hand, among patients with inﬂammatory disease
we found higher costs for patients with poorer physical
function and the need for assistive tools. Such subgroups of
patients could be in need for a more resource-demanding
and maybe longer rehabilitation period than others. More
research needs to identify patient groups which preferably
should receive inpatient or outpatient rehabilitation.
We expected that the healthcare costs prior to a reha-
bilitation stay were higher as compared to the period after
rehabilitation, in particular in the ﬁrst 3-month period
after the rehabilitation stay. An underlying assumption
was that patients with arthritis had a reduced need for
healthcare in the ﬁrst months following multidisciplinary
rehabilitation care of at least one-week duration. Opposite
to our expectations, the healthcare costs were surprisingly
high during the whole observation period, in particular
for the three clinical subgroups receiving rehabilitation at a
rehabilitation centre. Some of the increased costs right after
the rehabilitation stay might have been a consequence of
interventions that were initiated during the rehabilitation
stay followed up in the primary care after discharge. It
can also be argued that six months of follow-up was too
short time to show that the healthcare costs might have
reached the level prior to the rehabilitation stay. On the
other hand, similar to the ﬁndings in our study a recently
published observational study from Germany [6]r e p o r t e d
only minor diﬀerences in various healthcare costs (hospital,
medication, and physical therapy) in the year prior to and
the year after an inpatient or outpatient rehabilitation stay.
This might indicate that people with rheumatic diseases
have a relatively high and constant use of healthcare services
in a longer time perspective. Interestingly, healthcare costs
in our study are comparable to this German study [6], in
particular the mean hospital costs and costs for physical
therapy. Even though the studies were performed within
diﬀerent settings with diﬀerent health care systems, in both
Germany and Norway only minor diﬀerences exist for “out
of the pocket” expenses in rehabilitation settings which
in both countries are very low. Costs due to medication
use were higher for the patients with inﬂammatory disease
in the present study as compared to the German study,
because more of our patients used expensive biological
medication.
The mean direct cost of outpatient rehabilitation in our
study was about doubled compared to the German study [6]
and was even 5-6 times higher for inpatient hospital rehabil-
itation. Also compared to another observational study [21],
in which a mean cost of inpatient stay with multidisciplinary
rehabilitation for patients with RA was calculated to be
C2,494 (range 915–4,090), the costs estimated in our study10 Rehabilitation Research and Practice
wereabout fourfold.Since comprehensive inpatient and out-
patient multidisciplinary rehabilitation program have been
found to be equally eﬀective in patients with rheumatoid
arthritis, outpatient programmes are recommended [3–5].
Both this study and previous ﬁndings from the observational
study from Germany [6] suggest that there are similar
outcome of inpatient and outpatient rehabilitation and
hence support this recommendation.
The costs due to production loss associated with arthritis
exceeded by far the direct costs of healthcare. Although
this ﬁnding is similar to previous reviews of cost-of-illness
studies for patients with arthritis [9, 19], where indirect costs
are assumed to represent 50–75% of total costs, our results
should be interpreted with caution since only a minority of
the patients in our study were eligible for working.
Another limitation is the lower number of patients
in the outpatient group, which must be considered when
interpreting the results within this group. As mentioned
above, one might argue that 6-month follow-up was short
and a longer follow-up period could have helped to explore
whether costs due to healthcare consumption in the primary
care decreased back to the level prior to a rehabilitation stay.
Furthermore, the fact that the response rate at 6 months
of 66% and nonresponders were slightly younger and more
frequently single, with lower level of education and poorer
mental health, might indicate a potential for selection bias.
High rates of nonrespondents among younger people have
alsobeenreportedinotherstudiesusingmailedsurveys[22],
and it is not clear whether any of these factors inﬂuence
cost estimates. Although we had no intention or possibility
to draw any conclusions regarding cost-eﬀectiveness in this
study, the lack of a control group must also be considered as
a limitation.
The main strengths of this study were a large sample
size, further data for all study institutions were concurrently
collected, and investigation of the use of healthcare as well as
production loss after the rehabilitation stay was performed
in a detailed way. We also consider that this study has impli-
cations for further research. The observed large diﬀerences
in costs across clinical settings in which rehabilitation is
provided should be tested out in a randomised, controlled
trial in order to assess whether the increased costs can
be justiﬁed with increased eﬀectiveness. Moreover, it is
importanttoinvestigatewhetheragoodfollow-upprocedure
in the primary care can prevent or reduce the need for costly
inpatient multidisciplinary rehabilitation. Finally, the study
results can be used in a discussion regarding what is optimal
level of healthcare consumption and/or rehabilitation in
various subgroups of patients with arthritis. The patients in
this study had a lower level of healthcare consumption prior
to the rehabilitation period than afterwards. That might
seemcontradictoryasonewouldassumethattheircondition
was more severely aﬀected before than after. It is crucial
to understand the relationship between need and/or use of
healthcare consumption and severity of chronic diseases, in
order to develop longer-term optimal disease management
plans.
To conclude, our data demonstrated substantial costs
related to multidisciplinary rehabilitation care and use
of healthcare consumption among patients with arthritis,
before, during, and after the rehabilitation stay. The time
period following a scheduled rehabilitation stay was char-
acterized by surprisingly high healthcare consumption and
costs in patients with arthritis. Both the clinical setting
in which rehabilitation was provided and disease severity
itself had a large impact on healthcare consumption and
costs. In patients still working, indirect costs in terms
of sick leave were considerable. As a clinical implication,
methods to reduce the length of rehabilitation stay should
be developed, in particular at hospitals, and regarding
production loss with a focus on cost saving, given that
health outcomes are constant. Clinical studies on diﬀerent
rehabilitation strategies should include health-economic
analyses contributing to the best management of rheumatic
diseases.
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